Dj 10X Genomics Price Target Announced At $18.00/Share By Citigroup

What Happened?

Shares of biotech company 10x Genomics fell 6.3% in the morning session after Citigroup downgraded the stock to Neutral from Buy. 

The analyst firm adjusted its rating on the life science tools and diagnostics company, signaling a less optimistic outlook on its near-term performance. While Citigroup kept its price target for 10x Genomics unchanged at $18, the downgrade from a "Buy" rating was the key factor influencing investor sentiment. Such a change from an analyst can often lead investors to reconsider their position in a stock.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy 10x Genomics? Access our full analysis report here.

What Is The Market Telling Us

10x Genomics’s shares are extremely volatile and have had 50 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was 17 days ago when the stock gained 8.2% on the news that reports revealed the Trump administration considered extending the Affordable Care Act (ACA) subsidies. 

These subsidies, which are government financial aids to help people pay for health insurance, are crucial for insurers as they maintain a stable customer base. An extension would ensure continued revenue for companies with significant exposure to the ACA marketplace. The news prompted a strong positive reaction from investors, with Centene (CNC) shares jumping as much as 8%, Molina Healthcare (MOH) rising over 3%, and Oscar Health (OSCR) soaring 18%. The potential for a two-year extension reduces regulatory uncertainty for the sector, which investors view as a significant positive for the industry's outlook.

10x Genomics is up 16.3% since the beginning of the year, but at $16.51 per share, it is still trading 18% below its 52-week high of $20.13 from November 2025. Investors who bought $1,000 worth of 10x Genomics’s shares 5 years ago would now be looking at an investment worth $111.59.

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how life sciences tools & services stocks fared in Q3, starting with 10x Genomics .

The life sciences tools and services sector supports biotech and pharmaceutical R&D and commercialization by providing lab equipment, data analytics, and clinical trial services. These companies benefit from recurring revenue and high margins on specialized products. Looking ahead, the sector is supported by tailwinds like advancements in genomics, personalized medicine, and the use of AI in drug discovery. However, the persistent challenge is dependence on the R&D budgets of large pharmaceutical companies and the volatility of smaller biotech firms. Future headwinds include uncertain research funding and pricing pressures from cost-conscious customers.

The 21 life sciences tools & services stocks we track reported a strong Q3. As a group, revenues beat analysts’ consensus estimates by 1.7% while next quarter’s revenue guidance was 1% below.

Thankfully, share prices of the companies have been resilient as they are up 9.2% on average since the latest earnings results.

Best Q3: 10x Genomics

Founded in 2012 by scientists seeking to overcome limitations in traditional biological research methods, 10x Genomics develops instruments, consumables, and software that enable researchers to analyze biological systems at single-cell resolution and spatial context.

10x Genomics reported revenues of $149 million, down 1.7% year on year. This print exceeded analysts’ expectations by 4.6%. Overall, it was an incredible quarter for the company with a beat of analysts’ EPS estimates and revenue guidance for next quarter exceeding analysts’ expectations.

"Our team delivered a solid third quarter, and we continue to see notable enthusiasm for our single cell and spatial products," said Serge Saxonov, Co-founder and CEO of 10x Genomics.

Interestingly, the stock is up 37% since reporting and currently trades at $17.81.

Is now the time to buy 10x Genomics? Access our full analysis of the earnings results here, it’s free for active Edge members.

Sotera Health Company

With a critical role in ensuring the safety of millions of patients worldwide, Sotera Health (NASDAQGS:SHC) provides sterilization services, lab testing, and advisory services to ensure medical devices, pharmaceuticals, and food products are safe for use.

Sotera Health Company reported revenues of $311.3 million, up 9.1% year on year, outperforming analysts’ expectations by 2.6%. The business had an exceptional quarter with a solid beat of analysts’ full-year EPS guidance and organic revenue estimates.

However, the results were likely priced into the stock as it’s traded sideways since reporting. Shares currently sit at $16.75.

Is now the time to buy Sotera Health Company? Access our full analysis of the earnings results here, it’s free for active Edge members.

Weakest Q3: Avantor

With roots dating back to 1904 and embedded in virtually every stage of scientific research and production, Avantor provides mission-critical products, materials, and services to customers in biopharma, healthcare, education, and advanced technology industries.

Avantor reported revenues of $1.62 billion, down 5.3% year on year, falling short of analysts’ expectations by 1.4%. It was a softer quarter as it posted a slight miss of analysts’ revenue estimates and a miss of analysts’ organic revenue estimates.

Avantor delivered the slowest revenue growth in the group. As expected, the stock is down 26.9% since the results and currently trades at $11.02.

Read our full analysis of Avantor’s results here.

Charles River Laboratories

Named after the Massachusetts river where it was founded in 1947, Charles River Laboratories provides non-clinical drug development services, research models, and manufacturing support to pharmaceutical and biotechnology companies.

Charles River Laboratories reported revenues of $1.00 billion, flat year on year. This number surpassed analysts’ expectations by 1.1%. It was a satisfactory quarter as it also produced a narrow beat of analysts’ organic revenue estimates.

The stock is up 3.3% since reporting and currently trades at $183.71.

Read our full, actionable report on Charles River Laboratories here, it’s free for active Edge members.

Agilent

Originally spun off from Hewlett-Packard in 1999 as its measurement and analytical division, Agilent Technologies provides analytical instruments, software, services, and consumables for laboratory workflows in life sciences, diagnostics, and applied chemical markets.

Agilent reported revenues of $1.86 billion, up 9.4% year on year. This print beat analysts’ expectations by 1.5%. Overall, it was a strong quarter as it also logged an impressive beat of analysts’ organic revenue estimates and a narrow beat of analysts’ revenue estimates.

The stock is down 5.9% since reporting and currently trades at $144.76.

Read our full, actionable report on Agilent here, it’s free for active Edge members.